會(huì)議?1:?Protein & Antibody Engineering?蛋白質(zhì)與抗體工程

在中國(guó)舉辦聚焦于蛋白質(zhì)工學(xué)與抗體工學(xué)的會(huì)議

近年中國(guó)在全球生物醫(yī)藥產(chǎn)業(yè)中崛起，其真正價(jià)值不僅在監(jiān)管機(jī)構(gòu)的指導(dǎo)體制及審核路徑上、在新生物學(xué)治療藥物研發(fā)成果上也面臨考驗(yàn)。2017年3月28日至30日在中國(guó)上海舉辦的第4屆PEGS Summit，制藥企業(yè)高層與意見(jiàn)領(lǐng)袖齊聚一堂，針對(duì)創(chuàng)新的創(chuàng)藥議程、尖端技術(shù)成果、解決問(wèn)題的最佳實(shí)例與學(xué)習(xí)等主題展開(kāi)熱烈的討論。

2017年焦點(diǎn)：免疫療法作為癌癥治療創(chuàng)新方法的重要性日益升高，學(xué)會(huì)也新增了「癌癥免疫」相關(guān)分組討論會(huì)。本次會(huì)議不僅限于中國(guó)，將介紹全球制藥公司開(kāi)發(fā)免疫療法相關(guān)產(chǎn)品的生產(chǎn)線(xiàn)與計(jì)畫(huà)發(fā)展?fàn)顩r。

Preliminary Agenda

蛋白質(zhì)與抗體工程

本單元以蛋白質(zhì)及抗體工程為主題，研究機(jī)關(guān)與藥廠研究人員將分享蛋白質(zhì)及抗體分子的設(shè)計(jì)、新藥發(fā)現(xiàn)、工程研究成果，并討論克服開(kāi)發(fā)過(guò)程中所遇到各類(lèi)課題的創(chuàng)新策略。

暫定議程

聯(lián)合主題演講

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

DISPLAY LIBRARIES

A Novel Platform for Human Antibody Discovery Using Yeast Display Antibody Library

Aichi Zhao, Ph.D., President, R&D, OriMabs, Ltd.

Recombinant Antibody Display Libraries - Design, Construction and Selection

Eunice Zhou, Ph.D., Associate Adjunct Professor, Anesthesia, UC San Francisco

蛋白質(zhì)及抗體產(chǎn)生

Generation of Humanized Antibody Transgenic Animal (Camouse) for Producing Human Antibody

Liangpeng Ge, Ph.D., Director, Institute of Bingengineering, Chongqing Academy of Animal Sciences

New Techniques for in vitro Evolution and Selection of Enzymes

Manfred Konrad, Ph.D., Max-Planck Institute for Biophysical Chemistry, Head, Enzyme Biochemistry Laboratory

蛋白質(zhì)與標(biāo)靶工程

Case Study
Engineering G-Protein Coupled Receptors for High Production and Efficient Folding In Synthetic Environments

Frank Bernhard, Ph.D., Lab Manager, Biophysical Chemistry, Goethe University Frankfurt

Computationally-Driven Engineering of an Anti-Tumor Antibody

Chris Bailey-Kellogg, Ph.D., Professor, Computer Science, University of Dartmouth

新生物學(xué)治療藥物開(kāi)發(fā)

Engineering Anti-VEGFR2 X Anti-PDGFR-Beta Bispecific Antibodies for the Treatment of Cancer and Ophthalmological Diseases

Zhenping Zhu, Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corp, LLC.

Nexmab Antibody-Drug Conjugate for the Treatment of Ovarian Cancer

Sunbae Lee, Ph.D., Senior Research Scientist, R&D Center, Alteogen, Inc.

* 活動(dòng)內(nèi)容有可能不事先告知作更動(dòng)及調(diào)整。

蛋白質(zhì)聚集與穩(wěn)定性

近年，蛋白質(zhì)聚集、粒子、sub-visible particle相關(guān)研究變得越來(lái)越重要。聚集形成的機(jī)制，以及其發(fā)展和配方的影響，已成為許多研究與討論的主題。在本單元中，除了將分享動(dòng)力學(xué)研究成果以深入理解聚集原因，也聚焦提升穩(wěn)定性和控制聚集的分析及配方策略。

暫定議程

聯(lián)合主題演講

Engineering Single-Domain Antibodies for Cancer Therapy

Mitchell Ho, Ph.D., Chief, Antibody Therapy & Senior Investigator, National Institutes of Health

聚集形成

Determinant Factor for Aggregation and Fragment Formation: Oxidation

Joy Zhou, Ph.D., Principal Scientist, Associate Director, DP MST, Shire

Protein Aggregation during Formulation and Drug Product Manufacturing and Mitigation Strategies

Mark Yang Ph.D., Director, Fill Finish Development, BioPharmaceutical Development, Genzyme

發(fā)展性與處方開(kāi)發(fā)的聚集分析

Aggregation Analysis at High and Low Concentrations

Jennifer McManus, Ph.D., Lecturer, Department of Chemistry, National University of Ireland Maynooth

How to Optimize Stability of Drug Substance and Drug Product through Integration of Rapid and Sensitive Analytical Tools with Rational Approach to Developability Assessment and Early Formulation Development

Danny Chou, Ph.D., President, Compassion BioSolutions, LLC.

Heavy Chain of Mouse IgM Can Be Cleaved Between CH1 and CH2 Domains by a Protease Present in Serum

Tomasz Klaus, MSc, Research Assistant, Malopolska Centre of Biotechnology, Jagiellonian University, Krakow

穩(wěn)定性與傳輸裝置課題

Impact of Product Heterogeneity on Product Biological Activity and Stability in the Context of Bio-therapeutics

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd. (A Vitane Group of Companies)

Modified Phosphate Buffered Saline (PBS) as a Viable Vehicle for Biotherapeutic Drugs

Tatyana Mezhebovsky, Ph.D., Principal Scientist, BioFormulations, Sanofi US

* 活動(dòng)內(nèi)容有可能不事先告知作更動(dòng)及調(diào)整。

癌癥免疫

本單元以癌癥免疫為主題，本領(lǐng)域意見(jiàn)領(lǐng)袖及先驅(qū)研究人員，將討論中國(guó)目前研究現(xiàn)況，并聚焦推動(dòng)新分子至臨床研究階段的創(chuàng)新方法與尖端技術(shù)。

暫定議程

聯(lián)合主題演講

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Associate Professor, Oncology and Surgery, Gastrointestinal Cancer Program, Tumor Immunology Program, Johns Hopkins University School of Medicine

聯(lián)合會(huì)議－T細(xì)胞工程分析策略

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

中國(guó)癌癥領(lǐng)域PIPELINE與研究成果最新情報(bào)

Beyond PD-1: Challenge and Opportunity in Immuno-Oncology

Hongtao Lu, Ph.D., Executive Vice President & CSO, Discovery, Zai Laboratory

Improving the Efficacy of Immuno-Checkpoint Inhibitor through Target Mediated Antibody Recycling and Combination Interventions

Xueming Qian, Ph.D., Chairman & CEO, MabSpace Biosciences

Screening PD1 inhibitors and Beyond

Bo Chen, Ph.D., CEO, Shanghai Junshi

Updates on Alphamab's Molecules in the Clinic Targeting PDl-1 and CTLA-4

Ting Xu, Ph.D., CEO & President, Alphamab

The Design and Development of Novel Biologics for Cancer Immunotherapies

Jinming Gu, Ph.D., Executive Director, Biologics Discovery, Shanghai Hengrui Pharmaceutical Co., Ltd.

Novel Bispecific Antibody Technology for Cancer Immunotherapeutics

Chengbin Wu, Ph.D., CEO, Epimab

Amgen's BiTE Bispecific T-Cell Engaging Antibody for Immunotherapy

MingQiang Zhang, Ph.D., Head, R&D, Amgen Asia

Agonist Antibody in Immune-Oncology, in Mono- and Combination Therapies (tentative)

Peter Luo, Ph.D., CEO & Co-Founder, Adagene

* 活動(dòng)內(nèi)容有可能不事先告知作更動(dòng)及調(diào)整。

生物學(xué)治療藥物表徵分析

本單元以生物學(xué)治療藥表徵分析為主題，將重點(diǎn)擺在提供各種能加速技術(shù)創(chuàng)新的方法，將透過(guò)具獨(dú)創(chuàng)性的策略及最新技術(shù)研究發(fā)表，分享有助開(kāi)發(fā)具優(yōu)異特徵新生物學(xué)治療藥物的想法、專(zhuān)業(yè)知識(shí)、解決方案。

暫定議程

聯(lián)合主題演講

Multimodal Cancer Therapy - Dynamic Process-Based Immuno-oncology

Bertil Lindmark, M.D., Ph.D., CMO, ASLAN Pharmaceuticals

Rational Combination of Immune-Oncology Agents

Lei Zheng, Ph.D., Assistant Professor, Oncology and Gastrointestinal Cancer, Johns Hopkins University

聯(lián)合會(huì)議－T細(xì)胞工程的分析策略

Versatile Strategy for Controlling the Specificity and Activity of Engineered T Cells

Chan Hyuk Kim, Ph.D., Assistant Professor, Biological Sciences, KAIST

Applying a High Content Imaging Assay Platform to Elucidate the Mechanism of Actions of Cancer Immunotherapy

Ming Lei, Senior Research Investigator II, Lead Discovery and Optimization, Bristol-Myers Squibb Company

優(yōu)化與發(fā)展性

Integrated Technology Solutions to Support Biologics Hit to Lead and Beyond

Han Li, Ph.D., Principal Scientist, Leads Discovery & Optimization, Bristol-Myers Squibb Company

Mutational Approaches to Improve the Biophysical Properties of Single Domain Antibodies

Jamshid Tanha, Ph.D., Senior Research Officer, Human Health Therapeutics Portfolio, National Research Council Canada

新BIOSIMILAR產(chǎn)品結(jié)構(gòu)面與功能面表徵分析

Effects of Glycosylation on Biological Activities of Therapeutic Antibodies

Shan Chung, Ph.D., Senior Scientist and Group Leader, Bioanalytical Sciences, Genentech

Oxidative Post-Translational Modification - Impact on Stability and Formulation of Protein Therapeutics

Christian Schoeneich, Ph.D., Professor and Chair, Pharmaceutical Chemistry, University of Kansas Lawrence

Higher Order Structure Analysis of Antibodies by Hydrogen/Deuterium Exchange Mass Spectrometry

Susumu Uchiyama, Ph.D., Associate Professor, Graduate School of Engineering, Osaka University

Physicochemical and Functional Characterization of Biosimilar Bevacizumab

Ravish Patel, Ph.D., Scientist, Bioanalytical (Biologics), Analytical Development Lab, EPR Centre for Cancer Research and Bioinformatics Pvt. Ltd., India

* 活動(dòng)內(nèi)容有可能不事先告知作更動(dòng)及調(diào)整。